Supplement Table 1. Characteristics of patients performed ELISA
| Stage I (n=19) | Stage IV (n=12) | p Value | |
|---|---|---|---|
| Gender | |||
| Male | 4 | 10 | |
| Female | 15 | 2 | <0.001* |
| Age (yr) | 61 (44-68) | 42 (35-61) | 0.074 |
| Pack-year | 0 (0-2) | 18 (6-25) | <0.001* |
| Extrathoracic lesion | eye 18, skin 1, kidney1 | eye 5, skin 2 | |
| Serum CRP (mg/dl) | 0.1 (0.0-0.2) | 0.1 (0.1-0.2) | 0.700 |
| Serum LDH (IU/l) | 200 (163-213) | 182 (168-209) | 0.776 |
| Serum KL-6 (U/ml) | 324 (228-475)§ | 796 (559-1478) | 0.001* |
| Serum SP-D (ng/ml) | 34 (25-42)¶ | 108 (58-123) | <0.001* |
| Serum ACE (U/l) | 15 (13-21) | 20 (16-34) | 0.045* |
| Serum Lysozyme (μg/ml) | 8 (6-12) | 16 (9-21) | 0.030* |
| %VC (%) | 108.8 (102.8-119.7) | 91.9 (74.9-104.6) | 0.005* |
| %FEV1.0 (%) | 98.5 (93.0-114.1) | 88.5 (72.7-95.2) | 0.009* |
| BALF profiles | |||
| Recovery rate (%) | 59.3 (52.0-66.7) | 64.0 (53.0-67.9) | 0.556 |
| Cell density (×105/ml) | 2.4 (1.4-3.7) | 2.5 (1.4-4.1) | 0.685 |
| Macrophages (%) | 64.7 (44.9-74.0) | 72.0 (50.2-84.1) | 0.320 |
| Lymphocytes (%) | 32.8 (25.4-53.5) | 24.4 (14.0-48.9) | 0.265 |
| Neutrophils (%) | 0.0 (0.0-1.5) | 0.8 (0.2-1.4) | 0.125 |
| Eosinophils (%) | 0.0 (0.0-0.9) | 0.7 (0.0-1.2) | 0.256 |
| CD4/CD8 | 5.3 (3.4-9.0) | 5.7 (2.5-9.1) | 0.984 |
* p<0.05
§: n=17
¶: n=15.
Values are given as the numbers or medians (25th and 75th percentiles).
ELISA, enzyme-linked immunosorbent assay; KL-6, Krebs von den Lungen 6; SP-D, surfactant protein D; ACE, angiotensin converting enzyme; %VC, percentage of predicted vital capacity; %FEV1.0, percentage of forced expiratory volume in one second